Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists

Detalhes bibliográficos
Autor(a) principal: Pivatto Junior, Fernando
Data de Publicação: 2015
Outros Autores: Silva, André Luis Ferreira da, Bezerra, Indira Valente, Pires, Leonardo Martins, Amon, Luis Carlos, Blaya, Marina Bergamini, Scheffel, Rafael Selbach
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRGS
Texto Completo: http://hdl.handle.net/10183/158767
Resumo: Introduction: The use of risk scores for the assessment of major bleeding and stroke in patients with atrial fibrillation (AF) helps evaluate the risks and benefits of oral anticoagulation therapy. The aim of this study was to describe the percentage of patients receiving anticoagulants for non-valvular AF with a high risk of major bleeding based on the HAS-BLED score, as well as identify potential modifiable risk factors of bleeding and compare the risk of major bleeding with the risk of stroke. Methods: Retrospective cohort study involving patients of the anticoagulation outpatient clinic of the Division of Internal Medicine at Hospital de Clínicas de Porto Alegre. Major bleeding risk was estimated based on the HAS-BLED score and stroke risk was determined using the CHADS2 and CHA2DS2-VASc scores. Results: Sixty-three patients were investigated (mean age 74.3±10.9 years). The median HAS-BLED score was 2 points, 19 (30.2%) patients had a score ≥ 3 (high risk). The most prevalent modifiable risk factors were labile TP/INR (36.5%) and concomitant use of drugs (30.2%). The absolute risk of major bleeding based on the HAS-BLED score was higher than the risk of stroke in three (4.8%) and four (6.3%) patients in comparison with the CHADS2 and CHA2DS2-VASc score, respectively. Conclusions: We concluded that the percentage of patients with high risk of major bleeding is similar to the rate found in the national literature (30.2%). In addition, the most prevalent modifiable risk factors in our cohort were labile TP/INR and concomitant drug use.
id UFRGS-2_609cb30ea6af8efdedc154800c018213
oai_identifier_str oai:www.lume.ufrgs.br:10183/158767
network_acronym_str UFRGS-2
network_name_str Repositório Institucional da UFRGS
repository_id_str
spelling Pivatto Junior, FernandoSilva, André Luis Ferreira daBezerra, Indira ValentePires, Leonardo MartinsAmon, Luis CarlosBlaya, Marina BergaminiScheffel, Rafael Selbach2017-05-30T02:37:37Z20152357-9730http://hdl.handle.net/10183/158767001012994Introduction: The use of risk scores for the assessment of major bleeding and stroke in patients with atrial fibrillation (AF) helps evaluate the risks and benefits of oral anticoagulation therapy. The aim of this study was to describe the percentage of patients receiving anticoagulants for non-valvular AF with a high risk of major bleeding based on the HAS-BLED score, as well as identify potential modifiable risk factors of bleeding and compare the risk of major bleeding with the risk of stroke. Methods: Retrospective cohort study involving patients of the anticoagulation outpatient clinic of the Division of Internal Medicine at Hospital de Clínicas de Porto Alegre. Major bleeding risk was estimated based on the HAS-BLED score and stroke risk was determined using the CHADS2 and CHA2DS2-VASc scores. Results: Sixty-three patients were investigated (mean age 74.3±10.9 years). The median HAS-BLED score was 2 points, 19 (30.2%) patients had a score ≥ 3 (high risk). The most prevalent modifiable risk factors were labile TP/INR (36.5%) and concomitant use of drugs (30.2%). The absolute risk of major bleeding based on the HAS-BLED score was higher than the risk of stroke in three (4.8%) and four (6.3%) patients in comparison with the CHADS2 and CHA2DS2-VASc score, respectively. Conclusions: We concluded that the percentage of patients with high risk of major bleeding is similar to the rate found in the national literature (30.2%). In addition, the most prevalent modifiable risk factors in our cohort were labile TP/INR and concomitant drug use.application/pdfengClinical and biomedical research. Porto Alegre. Vol. 35, n. 2, (2015), p. 99-103HemorragiaAcidente vascular cerebralFibrilação atrialVarfarinaHemorrhageStrokeAtrial fibrillationWarfarinPhenprocoumonMajor bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonistsinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/otherinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSORIGINAL001012994.pdf001012994.pdfTexto completo (inglês)application/pdf710313http://www.lume.ufrgs.br/bitstream/10183/158767/1/001012994.pdfadf4bbec21fef13dbd0790f4a91ebd35MD51TEXT001012994.pdf.txt001012994.pdf.txtExtracted Texttext/plain21856http://www.lume.ufrgs.br/bitstream/10183/158767/2/001012994.pdf.txteb671410aee7a945e2ae4a1f7b610736MD5210183/1587672021-09-18 04:49:43.418693oai:www.lume.ufrgs.br:10183/158767Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2021-09-18T07:49:43Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.pt_BR.fl_str_mv Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists
title Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists
spellingShingle Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists
Pivatto Junior, Fernando
Hemorragia
Acidente vascular cerebral
Fibrilação atrial
Varfarina
Hemorrhage
Stroke
Atrial fibrillation
Warfarin
Phenprocoumon
title_short Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists
title_full Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists
title_fullStr Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists
title_full_unstemmed Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists
title_sort Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists
author Pivatto Junior, Fernando
author_facet Pivatto Junior, Fernando
Silva, André Luis Ferreira da
Bezerra, Indira Valente
Pires, Leonardo Martins
Amon, Luis Carlos
Blaya, Marina Bergamini
Scheffel, Rafael Selbach
author_role author
author2 Silva, André Luis Ferreira da
Bezerra, Indira Valente
Pires, Leonardo Martins
Amon, Luis Carlos
Blaya, Marina Bergamini
Scheffel, Rafael Selbach
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Pivatto Junior, Fernando
Silva, André Luis Ferreira da
Bezerra, Indira Valente
Pires, Leonardo Martins
Amon, Luis Carlos
Blaya, Marina Bergamini
Scheffel, Rafael Selbach
dc.subject.por.fl_str_mv Hemorragia
Acidente vascular cerebral
Fibrilação atrial
Varfarina
topic Hemorragia
Acidente vascular cerebral
Fibrilação atrial
Varfarina
Hemorrhage
Stroke
Atrial fibrillation
Warfarin
Phenprocoumon
dc.subject.eng.fl_str_mv Hemorrhage
Stroke
Atrial fibrillation
Warfarin
Phenprocoumon
description Introduction: The use of risk scores for the assessment of major bleeding and stroke in patients with atrial fibrillation (AF) helps evaluate the risks and benefits of oral anticoagulation therapy. The aim of this study was to describe the percentage of patients receiving anticoagulants for non-valvular AF with a high risk of major bleeding based on the HAS-BLED score, as well as identify potential modifiable risk factors of bleeding and compare the risk of major bleeding with the risk of stroke. Methods: Retrospective cohort study involving patients of the anticoagulation outpatient clinic of the Division of Internal Medicine at Hospital de Clínicas de Porto Alegre. Major bleeding risk was estimated based on the HAS-BLED score and stroke risk was determined using the CHADS2 and CHA2DS2-VASc scores. Results: Sixty-three patients were investigated (mean age 74.3±10.9 years). The median HAS-BLED score was 2 points, 19 (30.2%) patients had a score ≥ 3 (high risk). The most prevalent modifiable risk factors were labile TP/INR (36.5%) and concomitant use of drugs (30.2%). The absolute risk of major bleeding based on the HAS-BLED score was higher than the risk of stroke in three (4.8%) and four (6.3%) patients in comparison with the CHADS2 and CHA2DS2-VASc score, respectively. Conclusions: We concluded that the percentage of patients with high risk of major bleeding is similar to the rate found in the national literature (30.2%). In addition, the most prevalent modifiable risk factors in our cohort were labile TP/INR and concomitant drug use.
publishDate 2015
dc.date.issued.fl_str_mv 2015
dc.date.accessioned.fl_str_mv 2017-05-30T02:37:37Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/other
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10183/158767
dc.identifier.issn.pt_BR.fl_str_mv 2357-9730
dc.identifier.nrb.pt_BR.fl_str_mv 001012994
identifier_str_mv 2357-9730
001012994
url http://hdl.handle.net/10183/158767
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv Clinical and biomedical research. Porto Alegre. Vol. 35, n. 2, (2015), p. 99-103
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRGS
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Repositório Institucional da UFRGS
collection Repositório Institucional da UFRGS
bitstream.url.fl_str_mv http://www.lume.ufrgs.br/bitstream/10183/158767/1/001012994.pdf
http://www.lume.ufrgs.br/bitstream/10183/158767/2/001012994.pdf.txt
bitstream.checksum.fl_str_mv adf4bbec21fef13dbd0790f4a91ebd35
eb671410aee7a945e2ae4a1f7b610736
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv
_version_ 1815447631217819648